Abstract:Objective To evaluate the efficacy, recurrence control and safety of standardized moisturizing care in atopic dermatitis (AD). Methods Chinese randomized controlled trials (RCTs) published from database inception to September 2026 were retrieved from CNKI, Wanfang, VIP and CBM. Two reviewers independently screened and extracted data, assessed risk of bias with the Cochrane tool, and performed meta-analysis in RevMan 5.4. Results Ten RCTs (788 patients: 395 intervention, 393 control) were included. Compared with anti-inflammatory therapy alone, combined moisturizing care increased the total effective rate (RR=1.34, 95%CI: 1.24-1.45, I2=45%), reduced EASI (SMD=-1.09, 95%CI: -1.81 to -0.36, I2=87%), SCORAD (SMD=-0.94, 95%CI: -1.31 to -0.58, I2=36%) and pruritus scores (SMD=-1.26, 95%CI: -1.89 to -0.63, I2=85%), lowered recurrence risk (OR=0.17, 95%CI: 0.09-0.30, I2=0%), and did not significantly increase local adverse reactions (RR=0.40, 95%CI: 0.21-0.78, I2=34%); EASI and safety were sensitive to individual studies. Conclusion Combined with conventional anti-inflammatory therapy, standardized moisturizing care improves the total effective rate, alleviates skin lesions and pruritus, reduces recurrence and is well tolerated in AD, and may serve as a basic measure throughout the disease course.